bluebird bio, Inc.: Nasdaq/NYSE listing notice — bluebird bio receives Nasdaq notice for late 10-K filing due to restatement

bluebird bio, Inc.

Delayed 2023 Form 10-K due to restatement of 2022 annual and 2022/2023 quarterly financials.
Restatements relate to identification of embedded leases and treatment of non-lease components.
Company has until June 24, 2024 to submit plan to regain Nasdaq compliance; potential extension to Oct 14.
No impact on cash position or revenue expected from restatements.
Notice has no immediate effect on stock listing or trading.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

bluebird bio, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 24, 2024, bluebird bio, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company's delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the SEC. The Notice states

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001293971-24-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.